Abstract: Embodiments of the present invention relate to novel cytochrome P450 inhibitors and pharmaceutical compositions thereof having a disease-modifying action in the treatment of diseases associated with the production of cortisol that include metabolic syndrome, obesity, headache, depression, hypertension, diabetes mellitus, Cushing's Syndrome, pseudo-Cushing syndrome, cognitive impairment, dementia, heart failure, renal failure, psoriasis, glaucoma, cardiovascular disease, cancer, stroke or incidentalomas.

Abstract: Pharmaceutical compositions described in this document comprise 5-(phenoxymethyl)-1,3-dioxane analogs having a disease-modifying action in the treatment of diseases associated with the production of cortisol that include metabolic syndrome, obesity, headache, depression, hypertension, diabetes mellitus, Cushing's Syndrome, pseudo-Cushing syndrome, cognitive impairment, dementia, heart failure, renal failure, psoriasis, glaucoma, cardiovascular disease, cancer, stroke, incidentalomas, or any diseases involving the overproduction of cortisol.

Abstract: Embodiments of the present invention relate to novel cytochrome P450 inhibitors and pharmaceutical compositions thereof having a disease-modifying action in the treatment of diseases associated with the production of cortisol that include metabolic syndrome, obesity, headache, depression, hypertension, diabetes mellitus, Cushing's Syndrome, pseudo-Cushing syndrome, cognitive impairment, dementia, heart failure, renal failure, psoriasis, glaucoma, cardiovascular disease, cancer, stroke or incidentalomas.

Abstract: Embodiments of the present invention relate to 4-(phenoxymethyl)-1,3-dioxolane analogs and pharmaceutical compositions thereof having a disease-modifying action in the treatment of diseases associated with the overproduction of cortisol that include metabolic syndrome, and any involving the overproduction of cortisol.

Abstract: Embodiments of the present invention relate to novel cytochrome P450 inhibitors and pharmaceutical compositions thereof having a disease-modifying action in the treatment of diseases associated with the overproduction of cortisol that include metabolic syndrome, and any involving the overproduction of cortisol.

Abstract: The invention relates to a fitting for a vehicle seat, in particular for a motor vehicle seat, comprises a first fitting part and a second fitting part that can be rotated with respect to each other, a clip ring that is fixed to the first fitting part for holding both fitting parts axially together by an outer ring section and engaging the second fitting part by an inner annular section, and stops that define the limits of the relative rotation of both fitting parts and that comprise at least one limiting stop embodied as a clip ring and at least one locking stop joined to the second fitting part such that the limiting stop protrudes outwards from outside of the annular section of the clip ring, and the limiting stop is provided on a structural part secured to the second fitting part.

Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.

Abstract: A fitting for a vehicle seat, in particular for a motor vehicle seat, includes a first fitting part, on which a ring gear is formed, a second fitting part, on which a gear is formed. The gear meshes with the ring gear, whereby the two fitting parts are in transmission connection with each other. It also includes a rotatably supported eccentric for driving a relative rolling motion of the gear and the ring gear, wherein the eccentric rotates in the circumferential direction and is driven by a carrier. An installation space is provided between the first fitting part and the second fitting part, wherein a separating ring is arranged in the installation space. The separating ring divides the installation space into an outer installation space, and an inner installation space.

Abstract: For a fitting for a vehicle seat, in particular for a motor vehicle seat, comprising a first fitting part and a second fitting part, which are in a transmission connection with each other by means of a spur gear and a ring gear, which mesh with each other, and comprising a rotating eccentric driven by a carrier for driving a relative rolling motion of the spur gear and the ring gear, wherein the first fitting part accommodates the eccentric, which is supported on the second fitting part, the fitting is associated with one of at least two load classes and comprises components that are parameterized in regard to the associated load class and components that are carry-over parts for all load classes, wherein the fitting parts are parameterized components and the eccentric is one of the carry-over parts.

Abstract: For a fitting for a vehicle seat, in particular for a motor vehicle seat, comprising a first fitting part and a second fitting part, which are in a transmission connection with each other by means of a spur gear and a ring gear, which mesh with each other, and comprising a rotating eccentric driven by a carrier for driving a relative rolling motion of the spur gear and the ring gear, wherein the first fitting part accommodates the eccentric, which is supported on the second fitting part, the fitting is associated with one of at least two load classes and comprises components that are parameterized in regard to the associated load class and components that are carry-over parts for all load classes, wherein the fitting parts are parameterized components and the eccentric is one of the carry-over parts.

Abstract: The invention relates to a fitting for a vehicle seat, in particular for a motor vehicle seat, comprises a first fitting part and a second fitting part that can be rotated with respect to each other, a clip ring that is fixed to the first fitting part for holding both fitting parts axially together by an outer ring section and engaging the second fitting part by an inner annular section, and stops that define the limits of the relative rotation of both fitting parts and that comprise at least one limiting stop embodied as a clip ring and at least one locking stop joined to the second fitting part such that the limiting stop protrudes outwards from outside of the annular section of the clip ring, and the limiting stop is provided on a structural part secured to the second fitting part.

Abstract: A fitting for a vehicle seat, in particular for a motor vehicle seat, includes a first fitting part, on which a ring gear is formed, a second fitting part, on which a gear is formed. The gear meshes with the ring gear, whereby the two fitting parts are in transmission connection with each other. It also includes a rotatably supported eccentric for driving a relative rolling motion of the gear and the ring gear, wherein the eccentric rotates in the circumferential direction and is driven by a carrier. An installation space is provided between the first fitting part and the second fitting part, wherein a separating ring is arranged in the installation space. The separating ring divides the installation space into an outer installation space, and an inner installation space.

Abstract: The present invention relates to 4-aryl triazoles having the formula: wherein R1 is independently selected from the group consisting of: lower alkyl, lower alkenyl, lower alkynyl, lower heteroalkyl, lower heteroalkenyl, lower heteroalkynyl, heterocycloalkyl, heteroaryl, halo, CN, OR4, SR4, S(O)R4, S(O)2R4, and NR4R5; and Q is has the general formula: said compounds are useful in treating diseases associated with unwanted cytokine activity, inter alia, interleukin-1 (IL-1) and tumor necrosis factor (TNF) from cells.

Abstract: The present invention relates to 4-aryl triazoles having the formula: wherein R1 is independently selected from the group consisting of: lower alkyl, lower alkenyl, lower alkynyl, lower heteroalkyl, lower heteroalkenyl, lower heteroalkynyl, heterocycloalkyl, heteroaryl, halo, CN, OR4, SR4, S(O)R4, S(O)2R4, and NR4R5; and Q is has the general formula: said compounds are useful in treating diseases associated with unwanted cytokine activity, inter alia, interleukin-1 (IL-1) and tumor necrosis factor (TNF) from cells.

Abstract: The subject invention involves process for making fuctionalized oxazolidinones having structure (1) wherein: (a) R1 and R2 are each independently selected from hydrogen, alkyl, aryl and heterocycle, or R1 and R2 are attached to form a cycloalkyl, aryl or heterocyclic ring; (b) R3 is selected from primary and secondary alkly (—R6), —SO2—R4, and —C(O)NH—R5; (c) R4 is aryl; and (d) R5 is alkyl or aryl; the process comprising a reaction step carried out in a reaction mixture, wherein an oxazolidinone is reacted with an electrophile selected from R6-Br, R6-I, R4-SO2Cl, and R5-NCO; the reaction mixture comprising a non-protic and non-oxidizing solvent and potassium fluoride on alumina; and without the presence of a substantial amount of a strong base in the reaction mixture. The subject invention also involves libraries of functionalized oxazolidinone compounds and their preparation using such processes.

Abstract: The subject invention involves compounds having structure (I): wherein each R1 is independently alkyl, aryl, or heterocycle; each R2, R4, R7, and R8 is independently hydrogen or other substituent; A is aryl or heterocycle; and pharmaceutically acceptable forms thereof. The subject invention also involves pharmaceutical compositions containing such compounds, and methods for treating or preventing diseases or disorders using such compounds.

Abstract: The subject invention involves compounds having structure (I): wherein each R1 is independently alkyl, aryl, or heterocycle; each R2, R4, R7, and R8 is independently hydrogen or other substituent; A is aryl or heterocycle; and pharmaceutically acceptable forms thereof.

Abstract: The present invention relates to 4-aryl triazoles having the formula: 1

Abstract: The present invention relates to 4-aryl triazoles having the formula: 1